M&A / Deals Beeline raises $300m for BMS drugs, and other biofinancings PharmaphorumBeeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.M&A / DealsRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week. M&A / DealsRead full story Post navigation Previous: Most patients “won’t see benefit” with Alzheimer’s drugsNext: Revolution doubles stock offering target to $2B following pancreatic cancer win Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
